Safety and tolerability of MQX-503, a novel investigational topical formulation of nitroglycerin for the treatment of Raynaud's phenomenon

Naomi F. Rothfield(University of Connecticut), Fredrick M. Wigey, David H. Collier(Amgen (United States)), Janet Pope(St Joseph's Health Care), Maureen D. Mayes(The University of Texas Health Science Center), J. J. F. Belch(Ninewells Hospital), Richard W. Martin(Grand Rapids Community College), Lee Shapiro(Albany Medical Center Hospital), Sangeeta Sule(Johns Hopkins University), Mary Ellen Csuka(Medical College of Wisconsin), Bashar Kahaleh(University of Toledo), David Fiorentino(Stanford University), Virginia Steen(Georgetown University), Ariane L. Herrick(University of Salford), Vivien Hsu(Rutgers, The State University of New Jersey), Barry L. Gruber(State University of New York), Murray Baron(McGill University), Nadera Sweiss(University of Illinois Chicago), Robert W. Simms(Dartmouth–Hitchcock Medical Center), A Scheja(Ospedali Riuniti Umberto I), Christopher P. Denton(The Royal Free Hospital), Edwin Smith(Medical University of South Carolina), Joseph C. Shanahan(Duke University), Paul Emery, Leland W.K. Chung(VA Palo Alto Health Care System)
Lund University Publications (Lund University)
January 1, 2008
Cited by 1


Related Papers